Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 2
2012 1
2016 1
2018 1
2019 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Kuter DJ, et al. Lancet. 2008 Feb 2;371(9610):395-403. doi: 10.1016/S0140-6736(08)60203-2. Lancet. 2008. PMID: 18242413 Clinical Trial.
BACKGROUND: Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production. Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has been shown to …
BACKGROUND: Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction a …
Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM. Keating GM. Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. Drugs. 2012. PMID: 22316355 Review.
The efficacy of 12 or 24 weeks' therapy with subcutaneous romiplostim was compared with that of placebo in patients with ITP in three randomized, double-blind, multicentre, phase III trials. ...In conclusion, subcutaneous romiplostim is a …
The efficacy of 12 or 24 weeks' therapy with subcutaneous romiplostim was compared with that of placebo in patients wit …
Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.
Bylsma LC, Fryzek JP, Cetin K, Callaghan F, Bezold C, Mehta B, Wasser JS. Bylsma LC, et al. Am J Hematol. 2019 Jan;94(1):118-132. doi: 10.1002/ajh.25301. Epub 2018 Oct 21. Am J Hematol. 2019. PMID: 30264861 Free PMC article.
Immune thrombocytopenia (ITP) is a rare platelet disorder that is often persistent or chronic in adults. Patient management is dependent upon physician judgment and patient preference, given both the rarity of the condition and a paucity of high-qualit …
Immune thrombocytopenia (ITP) is a rare platelet disorder that is often persistent or chronic in adults. Patient manage …
Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Tarantino MD, et al. Lancet. 2016 Jul 2;388(10039):45-54. doi: 10.1016/S0140-6736(16)00279-8. Epub 2016 Apr 18. Lancet. 2016. PMID: 27103127 Clinical Trial.
BACKGROUND: The thrombopoietin receptor agonist romiplostim could be an effective treatment in symptomatic children with persistent or chronic immune thrombocytopenia. ...INTERPRETATION: In children with chronic immune thrombocytopenia, romip …
BACKGROUND: The thrombopoietin receptor agonist romiplostim could be an effective treatment in symptomatic children with persistent o …
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R. Shirasugi Y, et al. Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8. Epub 2011 Jun 25. Int J Hematol. 2011. PMID: 21706145 Clinical Trial.
The efficacy and safety of romiplostim, a thrombopoietin-mimetic peptibody, were evaluated in a double-blind, placebo-controlled, randomized trial of Japanese patients with chronic immune thrombocytopenia (ITP) …
The efficacy and safety of romiplostim, a thrombopoietin-mimetic peptibody, were evaluated in a double-blind, pl …
Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ. Sanz MA, et al. Value Health. 2011 Jan;14(1):90-6. doi: 10.1016/j.jval.2010.10.017. Value Health. 2011. PMID: 21211490 Free article.
No studies have addressed changes in utility in patients with chronic idiopathic thrombocytopenia (ITP). This study sought to assess the health utilities of patients with chronic ITP and to evaluate the association of change in health utility wi …
No studies have addressed changes in utility in patients with chronic idiopathic thrombocytopenia (ITP). This study sou …